New 25-Valent vaccine aims to broaden protection against pneumococcal disease
NCT ID NCT06077656
First seen Mar 27, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tested a new vaccine designed to protect against 25 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 220 healthy adults aged 18 to 49 received either the new vaccine or an existing one to compare safety and immune response. The goal was to see if the new vaccine is safe and triggers a strong immune reaction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL VACCINES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inventprise Clinical Site
Vancouver, British Columbia, V5Z 4H4, Canada
-
Inventprise Clinical Site
Halifax, Nova Scotia, B3K 6R8, Canada
-
Inventprise Clinical Site
Truro, Nova Scotia, B2N IL2, Canada
-
Inventprise Clinical Site
Saint-Louis, Quebec, G1W 4R4, Canada
Conditions
Explore the condition pages connected to this study.